New Drug to Treat Diabetes

A new molecule entity, ZYGK1 for treating diabetes, developed by Cadila Healthcare has been approved by the FDA in the US for the first phase of a clinical trial.

ZYGK1 is an Investigational New Drug (IND) taken orally as a glucokinase activator to identify glucose in the pancreas and to regulate glucose metabolism in the liver. When glucose levels rise above a certain level, the glucokinase enzyme enhances insulin release from pancreas and decreased glucose production in liver. In normal individuals, the pancreas secretes insulin in response to increased levels of glucose in the blood. But in patients with Type 2 diabetes, the GK activity is not sufficient in the pancreas and the liver.

Diabetes Type 1, Type 2 - Causes Symptoms Diagnosis and Treatment FAQs
A comprehensive article on diabetes - both Type 1 and Type 2 diabetes, including : causes, signs, symptoms, diagnosis, treatment, facts and a glossary on diabetes.

Cadila Healthcare will begin the phase I of a clinical trial for ZYGK1, Already in several preclinical models of Type 2 diabetes, ZYGK1 had proved its effectiveness in controlling both fasting and non-fasting blood glucose. Its safety profile was also good, the company claimed.

The chairman and managing director of Zydus Cadila group, Pankaj Patel, stated that the company was working towards addressing metabolic disorders and cardiovascular diseases.

Type 2 Diabetes - Risk Factors - Symptoms & Signs - Management - Prevention
Globalization and changing lifestyles has made diabetes very common in developing countries so much so that India is known as the Diabetes Capital of the World.

Source-Medindia

Diabetes Risk Assessment Calculator
Almost one-third of the people are unaware of the risk factors of diabetes. Find out if you run the risk of diabetes by using Diabetes Risk Assessment calculator.

Type 2 Diabetes
Learn more about Type 2 Diabetes, a disease that is taking the world by storm!